Both Zai Lab Limited (NASDAQ:ZLAB) and Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) are each other’s competitor in the Biotechnology industry. Thus the compare of their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab Limited	N/A	14127.81	139.07M	-2.65	0.00
Tetraphase Pharmaceuticals Inc.	18.90M	3.44	72.16M	-1.43	0.00

Table 1 demonstrates Zai Lab Limited and Tetraphase Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

	Net Margins	Return on Equity	Return on Assets
Zai Lab Limited	0.00%	0%	0%
Tetraphase Pharmaceuticals Inc.	-381.80%	-65.9%	-58%

Liquidity

The Current Ratio of Zai Lab Limited is 17.8 while its Quick Ratio stands at 17.8. The Current Ratio of rival Tetraphase Pharmaceuticals Inc. is 7.3 and its Quick Ratio is has 7.3. Zai Lab Limited is better equipped to clear short and long-term obligations than Tetraphase Pharmaceuticals Inc.

Analyst Ratings

Zai Lab Limited and Tetraphase Pharmaceuticals Inc. Recommendations and Ratings are available on the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Zai Lab Limited	0	0	0	0.00
Tetraphase Pharmaceuticals Inc.	0	0	2	3.00

Competitively the consensus price target of Tetraphase Pharmaceuticals Inc. is $5.5, which is potential 354.55% upside.

Institutional & Insider Ownership

The shares of both Zai Lab Limited and Tetraphase Pharmaceuticals Inc. are owned by institutional investors at 68.9% and 45.3% respectively. Zai Lab Limited’s share owned by insiders are 35.54%. Comparatively, Tetraphase Pharmaceuticals Inc. has 0.5% of it’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Zai Lab Limited	-2.13%	5.59%	54.72%	25.38%	30.14%	22.74%
Tetraphase Pharmaceuticals Inc.	8.47%	4.07%	-31.18%	-63.38%	-52.42%	13.27%

For the past year Zai Lab Limited was more bullish than Tetraphase Pharmaceuticals Inc.

Summary

On 6 of the 10 factors Zai Lab Limited beats Tetraphase Pharmaceuticals Inc.

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics for oncology, and autoimmune and infectious disease therapies in China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor for the treatment of ovarian, breast, and lung cancers; ZL-2401, an antibiotic for the treatment of acute bacterial skin/skin structure infections, community-acquired bacterial pneumonias, and urinary tract infections; ZL-2301 that is Phase II clinical trial for the treatment of hepatocellular carcinoma; ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; ZL-2302 for the treatment of non-small cell lung cancer; and ZL-1101, an anti-OX40 antagonistic antibody for the treatment of graft-versus-host disease or systemic lupus erythematosus. The company was founded in 2013 and is headquartered in Shanghai, China.

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. Its lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. The company has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy. It is also developing TP-271, a preclinical compound that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; and TP-6076, a second-generation Gram-negative program, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections. In addition, the company is involved in the discovery and development of additional antibiotics for the treatment of unmet medical needs, including multidrug-resistant Gram-negative bacteria. Tetraphase Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Watertown, Massachusetts.